2-Ethyl-4,5-diphenyl-1,2,3-triazol | 55324-03-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Ethyl-4,5-diphenyl-1,2,3-triazol
• 英文别名: 2-ethyl-4,5-diphenyl-2H-[1,2,3]triazole；2-Ethyl-4,5-diphenyl-2H-1,2,3-triazole；2-ethyl-4,5-diphenyltriazole
• CAS: 55324-03-3
• 化学式: C₁₆H₁₅N₃
• 分子量: 249.315
• InChiKey: SPJWTSYJKWOKFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4,5-Diphenyl-1H-[1,2,3]triazole 、 碘乙烷 以35%的产率得到
  参考文献：
  名称：

  GILCHRIST T. L.; GYMER G. E.; REES C. W., J. CHEM. SOC. PERKIN TRANS. , 1975, PART 1, NO 1, 1-8

  摘要：

  DOI：

文献信息

• TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20080038225A1

  公开（公告）日：2008-02-14

  The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.

  本发明涉及以下式I或II的化合物，或其药用盐、酯或前药：这些化合物抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰乙型肝炎病毒的生命周期，同时也可作为抗病毒剂使用。本发明还涉及包含上述化合物的药物组合物，用于治疗HCV感染的患者。该发明还涉及通过向患者施用包含本发明化合物的药物组合物来治疗患者的HCV感染的方法。
• TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20090047248A1

  公开（公告）日：2009-02-19

  The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.

  本发明涉及公式I或II的化合物，或其药学上可接受的盐、酯或前药：这些化合物抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰乙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及包含上述化合物的制剂，用于治疗患有HCV感染的受试者。本发明还涉及通过向受试者给予本发明化合物的制剂来治疗受试者的HCV感染的方法。
• General Solution to the Synthesis of <i>N</i>-2-Substituted 1,2,3-Triazoles
  作者：Xiao-jun Wang、Li Zhang、Dhileepkumar Krishnamurthy、Chris H. Senanayake、Peter Wipf

  DOI：10.1021/ol101965a

  日期：2010.10.15

  The regioselective N-alkylation of 1,2,3-triazoles 1-6 was studied Good to excellent N-2 selectivity and high chemical yields for N-2-substituted 4,5-dibromotriazoles 7 were obtained with 4,5-dibromo- and 4-bromo-5-trimethylsilyl-1,2,3-triazoles These building blocks can be readily converted to 2-mono-, 2,4-di-, and 2,4,5-polysubstituted triazoles 10-15, providing a general, protective, group-free method for the synthesis of N-2-substituted triazoles. Observed regioselectivities can be rationalized by a combination of Frontier Molecular Orbital, steric, and electrostatic directing effects on the heterocyclic scaffolds
• 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：Phadke Avinash

  公开号：US20100216725A1

  公开（公告）日：2010-08-26

  The invention provides 4-amino-4-oxobutanoyl peptides of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R 1 , R 6 -R 8 , R 16 , R 18 , R 19 , M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. The 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptides and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptides as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptides and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.
• US7662779B2
  申请人：——

  公开号：US7662779B2

  公开（公告）日：2010-02-16